Summary by Moomoo AI
On May 7, 2024, Incannex Healthcare Inc., a biotechnology company specializing in cannabinoid and psychedelic medicine, announced the successful completion of a pre-Investigational New Drug (pre-IND) meeting with the U.S. Food and Drug Administration (FDA) for their product CannQuit-O, aimed at treating Opioid Use Disorder (OUD). The meeting involved discussions with FDA representatives on the clinical development strategy for CannQuit-O, including patient populations, efficacy endpoints, and safety monitoring. The FDA provided recommendations that will guide Incannex in the data required to open an IND with the FDA and ensure successful clinical development. Dr. Mark Bleackley, Incannex's Chief Scientific Officer, emphasized the importance of developing new therapies like CannQuit-O to address the significant impact of OUD...Show More